Companies › Definium Therapeutics US
2 active drug programs in 5 registered trials: 4 Phase 3, 1 Phase 2; Psychiatry; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DT120 5-HT2A receptor agonist | HTR2A | Phase 3 | Major Depressive Disorder; Generalized Anxiety Disorder | Feb 2027 |
| Midomafetamine (DT402) Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Autism Spectrum Disorder | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06941844 | DT120 | Phase 3 | Major Depressive Disorder | Psychiatry | Feb 2027 |
| NCT06741228 | DT120 | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Apr 2027 |
| NCT06809595 | DT120 | Phase 3 | Generalized Anxiety Disorder | Psychiatry | May 2027 |
| NCT07303907 | Midomafetamine (DT402) | Phase 2 | Autism Spectrum Disorder | Psychiatry | Aug 2027 |
| NCT07592689 | DT120 | Phase 3 | Major Depressive Disorder | Psychiatry | Sep 2027 |
Cash and short-term investments of $1.1bn on 2026-06-30; operating cash outflow about $193m a year; runway about 67 months at that burn, to Feb 2032; 5 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Remedy Seaport Therapeutics Intra-Cellular Therapies Anavex Life Sciences Cybin IRL
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.